Mo X, Pei X, Huang X
Haematologica. 2024; 110(3):562-575.
PMID: 39568419
PMC: 11873716.
DOI: 10.3324/haematol.2024.286194.
Giannotti F, de Ramon Ortiz C, Simonetta F, Morin S, Bernardi C, Masouridi-Levrat S
Front Immunol. 2024; 15:1360275.
PMID: 38510239
PMC: 10950903.
DOI: 10.3389/fimmu.2024.1360275.
Munir F, Hardit V, Sheikh I, Alqahtani S, He J, Cuglievan B
Int J Mol Sci. 2023; 24(12).
PMID: 37373245
PMC: 10298672.
DOI: 10.3390/ijms241210095.
Leroyer E, Ziegler C, Moulin C, Campidelli A, Jacquet C, Rubio M
J Clin Med. 2022; 11(21).
PMID: 36362802
PMC: 9656939.
DOI: 10.3390/jcm11216574.
Stokes J, Molina M, Hoffman E, Simpson R, Katsanis E
Cancers (Basel). 2021; 13(7).
PMID: 33916711
PMC: 8038415.
DOI: 10.3390/cancers13071702.
Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients.
Castagna L, Busca A, Bramanti S, Raiola Anna M, Malagola M, Ciceri F
BMC Cancer. 2020; 20(1):1140.
PMID: 33234127
PMC: 7685618.
DOI: 10.1186/s12885-020-07602-w.
Haploidentical Stem Cell Transplantation in Lymphomas-Expectations and Pitfalls.
Mariotti J, Bramanti S, Santoro A, Castagna L
J Clin Med. 2020; 9(11).
PMID: 33171719
PMC: 7695017.
DOI: 10.3390/jcm9113589.
Salvage Therapy for Hodgkin's Lymphoma: A Review of Current Regimens and Outcomes.
Castagna L, Santoro A, Carlo-Stella C
J Blood Med. 2020; 11:389-403.
PMID: 33149713
PMC: 7603406.
DOI: 10.2147/JBM.S250581.
Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation.
Baumeister S, Rambaldi B, Shapiro R, Romee R
Front Immunol. 2020; 11:191.
PMID: 32117310
PMC: 7033970.
DOI: 10.3389/fimmu.2020.00191.
Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.
Vassilakopoulos T, Asimakopoulos J, Konstantopoulos K, Angelopoulou M
Ther Adv Hematol. 2020; 11:2040620720902911.
PMID: 32110285
PMC: 7026824.
DOI: 10.1177/2040620720902911.
Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR.
Fatobene G, Rocha V, Martin A, Hamadani M, Robinson S, Bashey A
J Clin Oncol. 2020; 38(14):1518-1526.
PMID: 32031876
PMC: 7213591.
DOI: 10.1200/JCO.19.02408.
Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT.
Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G
Blood Adv. 2020; 4(1):47-54.
PMID: 31899797
PMC: 6960457.
DOI: 10.1182/bloodadvances.2019000736.
Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience.
Roerden M, Sokler M, Kanz L, Bethge W, Vogel W, Walz J
Ann Hematol. 2020; 99(2):265-276.
PMID: 31897675
DOI: 10.1007/s00277-019-03900-x.
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.
Ahmed S, Kanakry J, Ahn K, Litovich C, Abdel-Azim H, Aljurf M
Biol Blood Marrow Transplant. 2019; 25(9):1859-1868.
PMID: 31132455
PMC: 6755039.
DOI: 10.1016/j.bbmt.2019.05.025.
Haploidentical Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Aggressive Lymphomas: How Far Have We Come and Where Are We Going?.
Patel D
World J Oncol. 2019; 10(1):1-9.
PMID: 30834047
PMC: 6396776.
DOI: 10.14740/wjon1164.
PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.
Dreger P, Sureda A, Ahn K, Eapen M, Litovich C, Finel H
Blood Adv. 2019; 3(3):360-369.
PMID: 30723110
PMC: 6373757.
DOI: 10.1182/bloodadvances.2018027748.
Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide.
Mariotti J, De Philippis C, Bramanti S, Sarina B, Tordato F, Pocaterra D
Eur J Haematol. 2019; 102(4):357-367.
PMID: 30672611
PMC: 7163667.
DOI: 10.1111/ejh.13214.
Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab.
Zappulo E, Nicolini L, di Grazia C, Dominietto A, Lamparelli T, Gualandi F
Infection. 2018; 47(1):59-65.
PMID: 30232604
DOI: 10.1007/s15010-018-1214-5.
Unique features and clinical importance of acute alloreactive immune responses.
Inman C, Eldershaw S, Croudace J, Davies N, Sharma-Oates A, Rai T
JCI Insight. 2018; 3(10).
PMID: 29769441
PMC: 6012511.
DOI: 10.1172/jci.insight.97219.
The early expansion of anergic NKG2A/CD56/CD16 natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation.
Roberto A, Di Vito C, Zaghi E, Mazza E, Capucetti A, Calvi M
Haematologica. 2018; 103(8):1390-1402.
PMID: 29700172
PMC: 6068034.
DOI: 10.3324/haematol.2017.186619.